Keratinocyte growth factor

被引：8

作者：

Athar, Uzma ^{[1
]}

Gentile, Teresa C. ^{[1
]}

机构：

[1] SUNY Upstate Med Univ, Reg Oncol Ctr, Div Hematol & Oncol, Dept Med, Syracuse, NY 13210 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2009年 / 9卷 / 06期

关键词：

hematologic malignancies; keratinocyte growth factor; KGF; oral mucositis; palifermin; prevention; VERSUS-HOST-DISEASE; ORAL MUCOSITIS; RANDOMIZED-TRIAL; PALIFERMIN; CHEMOTHERAPY; PROLIFERATION; REDUCTION; SURVIVAL; THERAPY; INJURY;

D O I：

10.1517/14712590902976837

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Mucositis occurs in over 90% of patients undergoing stem cell transplantation for hematological malignancies. It is associated with significant morbidity in the form of pain, dysphagia and decreased oral intake, as well as mortality. Palifermin is a recombinant keratinocyte growth factor that has been shown to be effective in decreasing the incidence, severity and duration of mucositis in Phase III trials. Improvement in patient functioning during hematopoietic stem cell transplants has also been reported. This review deals with the preclinical data and the clinical trials that have been carried out with this agent in patients with hematologic malignancies. In addition limited Phase I and II data on solid tumors is available and will be included.

引用

页码：779 / 787

页数：9

共 50 条

[1]

[Anonymous], PHASE 1 DOSE ESCALAT, Patent No. [NCT01345201, 01345201]

[2] Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17 [J].

Bamba, S ;

Andoh, A ;

Yasui, H ;

Araki, Y ;

Bamba, T ;

Fujiyama, Y .

JOURNAL OF GASTROENTEROLOGY, 2003, 38 (06) :548-554

[3] Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells [J].

Bao, SY ;

Wang, YJ ;

Sweeney, P ;

Chaudhuri, A ;

Doseff, AI ;

Marsh, CB ;

Knoell, DL .

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2005, 288 (01) :L36-L42

[4] Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) [J].

Blazar, Bruce R. ;

Weisdorf, Daniel J. ;

Defor, Todd ;

Goldman, Anne ;

Braun, Thomas ;

Silver, Samuel ;

Ferrara, James L. M. .

BLOOD, 2006, 108 (09) :3216-3222

[5] Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis [J].

Blijlevens, N. ;

Sonis, S. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :817-826

[6] Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma [J].

Brizel, David M. ;

Murphy, Barbara A. ;

Rosenthal, David I. ;

Pandya, Kishan J. ;

Glueck, Stefan ;

Brizel, Herbert E. ;

Meredith, Ruby F. ;

Berger, Dietmar ;

Chen, Mon-Gy ;

Mendenhall, William .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2489-2496

[7] Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation [J].

Criswell, T ;

Leskov, K ;

Miyamoto, S ;

Luo, GB ;

Boothman, DA .

ONCOGENE, 2003, 22 (37) :5813-5827

[8] Signal transduction by the JNK group of MAP kinases [J].

Davis, RJ .

CELL, 2000, 103 (02) :239-252

[9] The radiotherapeutic injury - a complex 'wound' [J].

Denham, JW ;

Hauer-Jensen, M .

RADIOTHERAPY AND ONCOLOGY, 2002, 63 (02) :129-145

[10] Reduction of oral mucositis by palifermin (rHuKGF):: Dose-effect of rHuKGF [J].

Dörr, W ;

Heider, K ;

Spekl, K .

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2005, 81 (08) :557-565

← 1 2 3 4 5 →